Table 1. Primary malignancy and time to... | American Society of Hematology

Table 1.

Primary malignancy and time to development of therapy-induced leukemia

ID no.	Diagnosis (FAB type)	Race	Primary malignancy	Treatment of primary malignancy^*	Time^† and type
1	M2	White	Osteogenic sarcoma	Methotrexate, anthracycline^‡	90 E
2	M2	White	Oligodendroglioma	CCG 921 (cyclophosphamide, cisplatin, CCNU^‡)	73 A
3^1-153	M4	White	Astrocytoma	CCNU, procarbazine^‡	25 E
4	M4	White	Ependymoma	CCG 921, CCG 9881 (VP-16^‡)	52 E
5	M5	White	ALL	CCG 1882 (anthracycline, cyclophosphamide^‡)	9 A/E
6^1-155	M5	White	Non-Hodgkin lymphoma	CCG 502 (cyclophosphamide, anthracycline, BCNU^‡)	56 A/E
7^1-155	M7	Other	Choroid plexus carcinoma	Cisplatin, cyclophosphamide, vincristine	33 A
8	M1	Black	Hodgkin disease	MOPP/ABVD	73 A/E
9	M4	Asian	ALL	CCG 1891 (cyclophosphamide, anthracycline^‡)	42 A/E
10	M5	White	Non-Hodgkin lymphoma	CCG 5911 (cyclophosphamide, anthracycline, ifosfamide^‡)	28 A/E
11	RAEB-T	White	ALL	CCG 1922 (anthracycline, cyclophosphamide^‡)	5 A/E
12	M6	White	ALL	CCG 1881 (anthracycline, cyclophosphamide^‡)	37 A/E
13	M5	Other	Ewing sarcoma	Anthracycline, cyclophosphamide^‡	25 A/E
14^1-153	RAEB-T	White	Hodgkin disease	MOPP/ABVD	38 A/E
15^1-153	M2	Hispanic	Ovarian germ cell	CCG 8891 (VP-16, cisplatin, bleomycin)	5 E
16^1-155	M5	White	Ewing sarcoma	Local protocol (anthracycline, cyclophosphamide^‡)	11 A/E
17	RAEB-T	White	Ewing sarcoma	CCG 7881+ local protocol (anthracycline, cyclophosphamide, ifosfamide^‡)	38 A/E
18^1-153	M5	White	Rhabdomyosarcoma	CCG 631 (anthracycline, cyclophosphamide, cisplatin^‡)	60 A/E
19^1-153	M4	Hispanic	Germ cell	Local protocol (VP-16)	Unknown E
20^1-155	M4	White	Hodgkin disease	CCG 521 (ABVD)	72 E
21^1-153	M4	Hispanic	Embryonal carcinoma	Cisplatin, VP16, bleomycin	13 E
22^1-155	M2	Black	Neuroblastoma	Cyclophosphamide, melphalan, DTIC	116 A
23	RAEB-T	Hispanic	Hodgkin disease	MOPP/ABVD	36 A/E
24	RAEB	Hispanic	ALL	MD Anderson protocol (etoposide^‡)	31 E

ID no.	Diagnosis (FAB type)	Race	Primary malignancy	Treatment of primary malignancy^*	Time^† and type
1	M2	White	Osteogenic sarcoma	Methotrexate, anthracycline^‡	90 E
2	M2	White	Oligodendroglioma	CCG 921 (cyclophosphamide, cisplatin, CCNU^‡)	73 A
3^1-153	M4	White	Astrocytoma	CCNU, procarbazine^‡	25 E
4	M4	White	Ependymoma	CCG 921, CCG 9881 (VP-16^‡)	52 E
5	M5	White	ALL	CCG 1882 (anthracycline, cyclophosphamide^‡)	9 A/E
6^1-155	M5	White	Non-Hodgkin lymphoma	CCG 502 (cyclophosphamide, anthracycline, BCNU^‡)	56 A/E
7^1-155	M7	Other	Choroid plexus carcinoma	Cisplatin, cyclophosphamide, vincristine	33 A
8	M1	Black	Hodgkin disease	MOPP/ABVD	73 A/E
9	M4	Asian	ALL	CCG 1891 (cyclophosphamide, anthracycline^‡)	42 A/E
10	M5	White	Non-Hodgkin lymphoma	CCG 5911 (cyclophosphamide, anthracycline, ifosfamide^‡)	28 A/E
11	RAEB-T	White	ALL	CCG 1922 (anthracycline, cyclophosphamide^‡)	5 A/E
12	M6	White	ALL	CCG 1881 (anthracycline, cyclophosphamide^‡)	37 A/E
13	M5	Other	Ewing sarcoma	Anthracycline, cyclophosphamide^‡	25 A/E
14^1-153	RAEB-T	White	Hodgkin disease	MOPP/ABVD	38 A/E
15^1-153	M2	Hispanic	Ovarian germ cell	CCG 8891 (VP-16, cisplatin, bleomycin)	5 E
16^1-155	M5	White	Ewing sarcoma	Local protocol (anthracycline, cyclophosphamide^‡)	11 A/E
17	RAEB-T	White	Ewing sarcoma	CCG 7881+ local protocol (anthracycline, cyclophosphamide, ifosfamide^‡)	38 A/E
18^1-153	M5	White	Rhabdomyosarcoma	CCG 631 (anthracycline, cyclophosphamide, cisplatin^‡)	60 A/E
19^1-153	M4	Hispanic	Germ cell	Local protocol (VP-16)	Unknown E
20^1-155	M4	White	Hodgkin disease	CCG 521 (ABVD)	72 E
21^1-153	M4	Hispanic	Embryonal carcinoma	Cisplatin, VP16, bleomycin	13 E
22^1-155	M2	Black	Neuroblastoma	Cyclophosphamide, melphalan, DTIC	116 A
23	RAEB-T	Hispanic	Hodgkin disease	MOPP/ABVD	36 A/E
24	RAEB	Hispanic	ALL	MD Anderson protocol (etoposide^‡)	31 E

RAEB-T indicates RAEB in transformation; A, alkylator-induced tMDS/tMDL; E, topoisomerase-induced. A/E, both agents involved.

Listing only of drugs most likely linked to tAML/tMDS. Treatment included drugs mentioned plus others not known to be associated with tMDS/tAML.

†

Time from primary malignancy in months.

‡

Other chemotherapeutic agents.

F1-153

Sample available for MLL gene rearrangement analysis and no rearrangement found.

F1-155

Sample available for MLL gene rearrangement analysis but DNA degraded.

View Large

This Feature Is Available To Subscribers Only